Concepedia

Mark C. Wilkes

MC

Statistics

Publications

27

Citations

3K

H-Index

21

Active since

1991

Affiliations

Mayo Clinic(Current)

Mayo Clinic in Florida

Mayo Clinic in Arizona

Stanford University

Stanford Medicine

Mark C. Wilkes is an author at Mayo Clinic specializing in cell signaling, life sciences, and signal transduction.

ORCID

Publications per year

1991–2021

27

Publications

27

Imatinib mesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycin-mediated lung fibrosis

Craig Daniels, Mark C. Wilkes, Maryanne Edens et al. · Journal of Clinical Investigation · 2004 · 525 citations · Full text

, , +16

Imatinib mesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycin-mediated lung fibrosis

Craig Daniels, Mark C. Wilkes, Maryanne Edens et al. · Journal of Clinical Investigation · 2004 · 486 citations · Full text

, , +16

Imatinib mesylate blocks a non‐Smad TGF‐β pathway and reduces renal fibrogenesis in vivo

Shinong Wang, Mark C. Wilkes, Edward B. Leof et al. · The FASEB Journal · 2005 · 462 citations

, , +17

Transforming Growth Factor-β Activation of Phosphatidylinositol 3-Kinase Is Independent of Smad2 and Smad3 and Regulates Fibroblast Responses via p21-Activated Kinase-2

Mark C. Wilkes, Hugh Mitchell, Sumedha G. Penheiter et al. · Cancer Research · 2005 · 213 citations · Full text

, , +15

Role of VEGF receptor-1 (Flt-1) in mediating calcium-dependent nitric oxide release and limiting DNA synthesis in human trophoblast cells.

Asif Ahmed, Caroline Dunk, Douglas A. Kniss et al. · PubMed · 1997 · 154 citations

, , +12

1–5 of 27